Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allograft Vasculopathy
Reports by L. Potena and co-researchers describe recent advances in allograft vasculopathy
July 22nd, 2008
According to a study from Bologna, Italy, "Folic acid therapy reduces homocysteine plasma levels, which seem to influence occurrence of cardiac allograft vasculopathy, but its effect on medium- or long-term prognosis after heart transplantation is unknown. We analyzed 7-year outcome of 51 recipients randomized to receive 15 mg/day of methyltertrahydrofolate for I year after heart transplantation or standard therapy alone (originally, for intravascular ultrasound study of short-term cardiac allograft vasculopathy progression); recipients were observed for a further 5 to 6 years." "Overall, 13 deaths occurred (six oncologic, five cardiovascular, two infective). Estimated...
Source: Cancer Weekly (2008-07-22)
|
